Levetiracetam (All indications) updated on 04-22-2025

Elective/induced termination of pregnancy

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19339
R81980		 Moore (Controls exposed to LTG) (Levetiracetam) (Indication NOS), 2025 Elective termination of pregnancy during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.69 [0.56;0.85] C
excluded (control group) 		141/1,011   351/1,846 492 1,011
ref
S19333
R81956		 Moore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025 Elective termination of pregnancy during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Matched 0.82 [0.63;1.05] 141/1,011   1,478/9,448 1,619 1,011
ref
S16096
R66786		 Hoeltzenbein (Levetiracetam), 2024 Elective termination of pregnancy at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: Yes 1.05 [0.26;4.23] 7/221   6/469 13 221
ref
S12676
R47900		 Mari (Levetiracetam), 2022 Abortion throughout pregnancy retrospective cohort exposed to other treatment, sick Adjustment: No 0.64 [0.01;34.59] C 0/17   0/11 0 17
ref
S12886
R48696		 Hosny (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021 Induced abortion 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.01 [0.00;0.92] C
excluded (control group) 		0/67   0/1 0 67
ref
S12887
R48699		 Hosny (Levetiracetam) (Controls unexposed, sick), 2021 Induced abortion 1st trimester prospective cohort unexposed, sick Adjustment: No 0.31 [0.01;16.03] C 0/67   0/21 0 67
ref
Total 4 studies 0.82 [0.64;1.06] 1,632 1,316
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Moore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025Moore, 2025 1 0.82[0.63; 1.05]1,6191,01196%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: low Hoeltzenbein (Levetiracetam), 2024Hoeltzenbein, 2024 2 1.05[0.26; 4.23]132213%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: criticalROB reporting: critical Mari (Levetiracetam), 2022Mari, 2022 3 0.64[0.01; 34.59]0170%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: unclear Hosny (Levetiracetam) (Controls unexposed, sick), 2021Hosny, 2021 4 0.31[0.01; 16.03]0670%ROB confusion: criticalROB selection: moderateROB classification: unclearROB missing: lowROB mesure: unclearROB reporting: moderate Total (4 studies) I2 = 0% 0.82[0.64; 1.06]1,6321,3160.25.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, general pop) (Levetiracetam) (Indication NOS; 2: Levetiracetam; 3: Levetiracetam; 4: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.82[0.64; 1.06]1,6321,3160%NAMoore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025 Hoeltzenbein (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Hosny (Levetiracetam) (Controls unexposed, sick), 2021 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.82[0.64; 1.06]1,6191,011 -NAMoore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025 1 unexposed, sickunexposed, sick 0.31[0.01; 16.03]-67 -NAHosny (Levetiracetam) (Controls unexposed, sick), 2021 1 exposed to other treatment, sickexposed to other treatment, sick 0.99[0.27; 3.71]132380%NAHoeltzenbein (Levetiracetam), 2024 Mari (Levetiracetam), 2022 2 Tags Adjustment   - No  - No 0.44[0.03; 7.32]-840%NAMari (Levetiracetam), 2022 Hosny (Levetiracetam) (Controls unexposed, sick), 2021 2   - Yes  - Yes 0.83[0.64; 1.06]1,6321,2320%NAMoore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025 Hoeltzenbein (Levetiracetam), 2024 2 MatchedMatched 0.82[0.64; 1.06]1,6191,011 -NAMoore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025 1 All studiesAll studies 0.82[0.64; 1.06]1,6321,3160%NAMoore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025 Hoeltzenbein (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Hosny (Levetiracetam) (Controls unexposed, sick), 2021 40.15.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.84.62.4460.000Moore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025Hoeltzenbein (Levetiracetam), 2024Mari (Levetiracetam), 2022Hosny (Levetiracetam) (Controls unexposed, sick), 2021

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 12886, 19339

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.82[0.64; 1.06]1,6191,011 -NAMoore (Controls unexposed, general pop) (Levetiracetam) (Indication NOS), 2025 1 unexposed, sick controlsunexposed, sick controls Out of scale0.31[0.01; 16.03]-67 -NAHosny (Levetiracetam) (Controls unexposed, sick), 2021 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.68[0.34; 1.38]5051,31620%NAMoore (Controls exposed to LTG) (Levetiracetam) (Indication NOS), 2025 Hoeltzenbein (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Hosny (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021 40.510.01.0